Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Launched by PFIZER · Jul 15, 2008
Trial Information
Current as of July 08, 2025
Completed
Keywords
ClinConnect Summary
All the patients whom an investigator prescribes the first SUNITINIB MALATE(Sutent) should be registered.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients need to be administered SUNITINIB MALATE(Sutent) in order to be enrolled in the surveillance.
- Exclusion Criteria:
- • Patients not administered SUNITINIB MALATE(Sutent).
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials